SCHEMBL4659846

SCHEMBL4659846

Cc1n[nH]c2ccc(-c3cc(NC[C@H](N)Cc4c[nH]c5ccccc45)cnc3-c3cc(F)ccc3O)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.48
FGFR2 P21802 3/20 0.48
FGFR3 P22607 3/20 0.48
ABL1 P00519 2/20 0.48
EGFR P00533 2/20 0.48
INSR P06213 2/20 0.48
RET P07949 2/20 0.48
SRC P12931 2/20 0.48
FGFR4 P22455 2/20 0.48
LTK P29376 2/20 0.48
KDR P35968 2/20 0.48
MERTK Q12866 2/20 0.48
ERBB4 Q15303 2/20 0.48
ALK Q9UM73 2/20 0.48
FLT1 P17948 1/20 0.48
MAPK1 P28482 1/20 0.48
DDR2 Q16832 1/20 0.48
AKT1 P31749 17/20 0.47
ROCK1 Q13464 3/20 0.47
RPS6KB1 P23443 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659851 1.00 FGFR1 (0.48) FGFR1FGFR2FGFR3ABL1EGFR
SCHEMBL4658629 0.93 AKT1 (0.48) FGFR1FGFR2FGFR3INSRKDR
SCHEMBL4658638 0.93 AKT1 (0.48) FGFR1FGFR2FGFR3INSRKDR
SCHEMBL4659464 0.91 AKT1 (0.46) FGFR1INSRKDRMAPK1AKT1
SCHEMBL4659462 0.91 AKT1 (0.46) FGFR1INSRKDRMAPK1AKT1
SCHEMBL4659784 0.87 AKT1 (0.63) FGFR1INSRKDRMAPK1AKT1
SCHEMBL4659785 0.87 AKT1 (0.63) FGFR1INSRKDRMAPK1AKT1
SCHEMBL4660762 0.86 AKT1 (0.56) FGFR1INSRKDRMAPK1AKT1
SCHEMBL4660764 0.86 AKT1 (0.56) FGFR1INSRKDRMAPK1AKT1
SCHEMBL5472520 0.85 AKT1 (0.61) FGFR1AKT1ROCK1RPS6KB1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720855-A4 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORP (US) 2008-12-17 EP claimed
US-20070185152-A1 Inhibitors of akt activity SMITHKLINE BEECHAM CORPORATION 2007-08-09 US claimed
EP-1720855-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP claimed
WO-2005085227-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-09-15 WO claimed
EP-1720855-A4 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORP (US) 2008-12-17 EP disclosed
US-20070185152-A1 Inhibitors of akt activity SMITHKLINE BEECHAM CORPORATION 2007-08-09 US disclosed
EP-1720855-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005085227-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185152-A1 Inhibitors of akt activity AKT1, AKT1S1, AKT2 FGFR1 1565/4885FGFR2 1337/4885FGFR3 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.